For the first time, WHO’s treatment pointers contain a transparent suggestion for the usage of prolonged-performing injectable cabotegravir and rilpivirine (Taxi/RPV) in its place switching option for antiretroviral therapy (ART) for adults and adolescents that have attained entire viral suppression on oral ART and do not have Lively hepatitis B https://maps.app.goo.gl/SucmaxKzrENyUBfj9